- Home
- PLX vs NTHI Comparison
PLX vs NTHI Comparison
Compare PLX & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- NTHI
- Stock Information
- Founded
- PLX 1993
- NTHI 2008
- Country
- PLX United States
- NTHI United States
- Employees
- PLX N/A
- NTHI N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- PLX Health Care
- NTHI Health Care
- Exchange
- PLX Nasdaq
- NTHI Nasdaq
- Market Cap
- PLX 204.9M
- NTHI 211.9M
- IPO Year
- PLX 1998
- NTHI N/A
- Fundamental
- Price
- PLX $1.85
- NTHI $10.35
- Analyst Decision
- PLX Strong Buy
- NTHI
- Analyst Count
- PLX 1
- NTHI 0
- Target Price
- PLX $15.00
- NTHI N/A
- AVG Volume (30 Days)
- PLX 1.1M
- NTHI 58.8K
- Earning Date
- PLX 11-13-2025
- NTHI 11-19-2025
- Dividend Yield
- PLX N/A
- NTHI N/A
- EPS Growth
- PLX N/A
- NTHI N/A
- EPS
- PLX 0.08
- NTHI N/A
- Revenue
- PLX $61,948,000.00
- NTHI $59,990.00
- Revenue This Year
- PLX $14.53
- NTHI N/A
- Revenue Next Year
- PLX $75.77
- NTHI N/A
- P/E Ratio
- PLX $24.02
- NTHI N/A
- Revenue Growth
- PLX 62.79
- NTHI N/A
- 52 Week Low
- PLX $1.01
- NTHI $3.20
- 52 Week High
- PLX $3.10
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- PLX 38.39
- NTHI N/A
- Support Level
- PLX $2.31
- NTHI N/A
- Resistance Level
- PLX $2.55
- NTHI N/A
- Average True Range (ATR)
- PLX 0.15
- NTHI 0.00
- MACD
- PLX -0.06
- NTHI 0.00
- Stochastic Oscillator
- PLX 23.70
- NTHI 0.00
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).